As of June 2026, the company has a market capitalization of approximately $377 million. The company appears to be in growth phase, with total revenues of $82.5 million in 2023 compared to $51.3 million in 2022, representing 61% year-over-year growth.
Cyborg Score Rationale
G1 Therapeutics demonstrates strong revenue growth trajectory and commercial execution in oncology, but faces profitability challenges with accumulated deficit and declining market valuation (trading at $7.15 vs. IPO price of $15.00). The company maintains public market access and active pipeline development.
Top Insights
Revenue growth accelerating: 61% YoY increase from 2022 to 2023 ($51M to $82.5M), demonstrating commercial traction
Capital constraints evident: Market cap ~$377M with accumulated deficit of $780M as of end-2023
Stock underperformance: Trading significantly below 2017 IPO price of $15.00, currently at $7.15 as of June 2026
Commercial-stage execution: Company transitioning from clinical to revenue-generating products in oncology space
Named Competitors
Checkpoint inhibitors / Cancer therapeutics — Oncology and inflammatory disease therapeutics
Cell cycle regulation — Cell cycle and checkpoint control therapeutics
Recent Developments
(May 2026) Stock trading at $7.15 per share on NASDAQ (GTHX ticker)
Open the full interactive G1 Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.